Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 15 Waldenstrom Macroglobulinemia 1 Recurrence 1 Neoplasm, Residual 1 Myasthenia Gravis 1 Leukemia, Plasma Cell 1 Infections 1 Immunoglobulin Light-chain Amyloidosis 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 21 Cytarabine 15 blinatumomab 13 fludarabine 12 Azacitidine 10 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Methotrexate 7 Lenalidomide 7 Dexamethasone 7 Rituximab 6 Mercaptopurine 6 Daunorubicin 6 Vincristine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Etoposide 4 Busulfan 4 obinutuzumab 3 Radiotherapy 3 Neoadjuvant Therapy 3 Maintenance 3 Liquid Biopsy 3 Immunotherapy, Adoptive 3 Idarubicin 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Doxorubicin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasm, Residual × talquetamab × Clear all

NCT06993675 2026-05-13

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡